Prof Simon Lewis describes the press release reporting the 12 month data of the PASADENA study evaluating prasinezumab, a novel monoclonal antibody aiming to slow disease progression in patients with early stage Parkinson’s Disease.
Prof Simon Lewis describes the press release reporting the 12 month data of the PASADENA study evaluating prasinezumab, a novel monoclonal antibody aiming to slow disease progression in patients with early stage Parkinson’s Disease.
For the latest developments and research.
You cannot copy content of this page